Tradestie Institutional Equity Comparison Engine
CVM vs OBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CVM Overall Edge
CVM Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs OBIO N/M Fwd P/E
Growth & Margin Winner
CVM
Op Margin 0.0% vs -195.4% ยท YoY -62.7% vs -89.4%
Momentum & Technical Winner
OBIO
1Y -73.0% vs +78.2% ยท 52W Pos 15% vs 89%
Options & Structure Winner
OBIO
BREAKDOWN (N/A IV) vs BREAKOUT (<1st %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap
$22.5M
1M Return
+15.45%
1Y Return
-72.98%
Forward P/E
23.0x
Unified AI Score
43.5 / 100
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap
$570.6M
1M Return
+24.25%
1Y Return
+78.17%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -72.98%
OBIO +78.17%
Spread: +149.39 pp (OBIO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | OBIO Revenue | CVM Op. Margin | OBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | $0M | N/A | -1881.0% | N/A | CVM |
| FY2012 | $0M | N/A | -6772.3% | N/A | CVM |
| FY2013 | $0M | N/A | -12450.1% | N/A | CVM |
| FY2014 | $0M | N/A | -9721.4% | N/A | CVM |
| FY2022 | N/A | $0M | N/A | -924.3% | OBIO |
| FY2023 | N/A | $0M | N/A | -1866.2% | OBIO |
| FY2024 | N/A | $0M | N/A | -2437.5% | OBIO |
| FY2025 | N/A | $30M | N/A | -154.7% | OBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | OBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $22.5M | $570.6M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -62.7% | -89.4% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | 0.0% | -195.4% | Higher Margin | CVM |
| Net Profit Margin Profitability | 0.0% | -182.5% | Higher Margin | CVM |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -182.3% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 15% ($1โ$8) | 89% ($3โ$7) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 0.45ฮฒ ยท 139% Vol | 1.15ฮฒ ยท 80% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs OBIO Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
OBIO
BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.